Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
217 hedge funds and large institutions have $3.9B invested in Soleno Therapeutics in 2025 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 74 increasing their positions, 55 reducing their positions, and 17 closing their positions.
306% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 17
138% more funds holding in top 10
Funds holding in top 10: 8 → 19 (+11)
70% more capital invested
Capital invested by funds: $2.29B → $3.9B (+$1.61B)
35% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 55
31% more funds holding
Funds holding: 166 → 217 (+51)
21% more call options, than puts
Call options by funds: $285M | Put options by funds: $236M
0.62% more ownership
Funds ownership: 118.37% → 118.99% (+0.62%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$78.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$69.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$44.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$106M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$89.3M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$47.6M |
| 4 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$25.1M |
| 5 |
CC
Commodore Capital
New York
|
-$18.3M |
SLNO Hedge Fund Activity: Q1 2025 in Review
217 of the 7,466 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2025, worth a combined $3.9B — up 70% from $2.29B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new SLNO positions and 17 closed out — a net gain of 52 holders — while 74 added to existing stakes and 55 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $78.7M. The largest seller was Nantahala Capital Management, cutting an estimated $106M.
- 217 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2025, up from 166 in Q4 2024.
- Funds reported $3.9B of Soleno Therapeutics stock for Q1 2025, up 70% quarter-over-quarter.
- 69 funds opened new Soleno Therapeutics positions in Q1 2025 and 17 closed out, a net change of +52 holders.
- The largest Soleno Therapeutics buyer in Q1 2025 was Adage Capital Partners, an estimated $78.7M added.
- The largest Soleno Therapeutics seller in Q1 2025 was Nantahala Capital Management, an estimated $106M sold.
Based on aggregated 13F filings for Q1 2025.